EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

A narrow therapeutic window of platelet P2Y 12 reactivity in high-risk Chinese percutaneous coronary intervention patients

Liying Gong, Yaxin Liu, Jingle Li, Shiming Tan, Chengxian Guo, Zhengmei Wang, Huiling Song, Yun Kuang, Yu Cao, Guoping Yang

PeerJ · 2026

DOI: 10.7717/peerj.20536 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift PeerJ, 2026. Verfasst von Liying Gong und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, China. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Purinergic P2Y Receptor Antagonists, Blood Platelets, Receptors, Purinergic P2Y12. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Research and Development Project of Hunan Province, National Major New Drug Creation Project of China, Health Research Project of Hunan Provincial Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Much evidence has been provided that a therapeutic window of P2Y 12 receptor inhibition exists, which is highly significantly associated with ischemic and bleeding events. The therapeutic window for high-risk stratification after percutaneous coronary intervention (PCI) is lacking. We aimed to investigate the therapeutic window of P2Y 12 receptor inhibition in high-risk Chinese PCI patients.

Methods

In this observational study, we analyzed 860 high-risk patients who were undergoing PCI. The primary endpoint was the correlation between vasodilator-stimulated phosphoprotein platelet reactivity index (VASP-PRI) values with bleeding and ischemic components in high-risk patients. The secondary endpoint was a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, urgent revascularization, and stroke at 12 months after the index procedure.

Results

Among high-risk patients, VASP-PRI could significantly discriminate between PCI patients with and without ischemic events (area under the curve (AUC): 0.77; 95% CI [0.72–0.82]; P < 0.001). A VASP-PRI ≥ 0.45 was the optimal cutoff point to predict ischemic events (sensitivity: 86.6%; specificity: 63.6%). Similarly, VASP-PRI could also significantly discriminate between PCI patients with and without bleeding events ((AUC): 0.77; 95% CI [0.73–0.81]; P < 0.001). A VASP-PRI ≤ 0.24 was the optimal cutoff point to predict bleeding events (sensitivity: 72.1%; specificity: 70.3%). Multivariate analysis showed that VASP-PRI was an independent predictor of the risk of major adverse cardiovascular events (odds ratio: 10.67, 95% CI [3.78–30.08]).

Conclusion

Our results suggest that high-risk Chinese PCI patients have a narrow therapeutic window. Within this window, high-risk patients are at lower risk for both ischemic and bleeding events. Platelet reactivity may have significant implications for personalized antiplatelet therapy in high-risk patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Percutaneous Coronary InterventionPurinergic P2Y Receptor AntagonistsBlood PlateletsReceptors, Purinergic P2Y12Platelet Aggregation InhibitorsHumansMaleFemaleMiddle AgedAgedChinaVasodilator-Stimulated PhosphoproteinCell Adhesion MoleculesPhosphoproteinsMicrofilament ProteinsHemorrhageEast Asian People

Stichwörter der Autor:innen

Dual antiplatelet therapyHigh-riskPercutaneous coronary interventionPlatelet reactivity

Substanzen

Purinergic P2Y Receptor AntagonistsReceptors, Purinergic P2Y12Platelet Aggregation InhibitorsVasodilator-Stimulated PhosphoproteinCell Adhesion MoleculesPhosphoproteinsMicrofilament Proteins

Autor:innen und Institutionen

  • Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, China.
  • Department of the Critical Care Medicine, The Third Xiangya Hospital, Central South University, Changsha, China.
  • Department of Cardiology, The Third Xiangya Hospital, Central South University, Changsh, China.
  • Department of the Clinical Hematology Laboratory, The Third Xiangya Hospital, Central South University, Changsha, China.
  • XiangYa School of Pharmaceutical Sciences, Central South University, Changsha, China.

Förderung

  • Key Research and Development Project of Hunan Province
  • National Major New Drug Creation Project of China
  • Health Research Project of Hunan Provincial Health Commission

Zitieren

APA

Gong, L., Liu, Y., Li, J., Tan, S., Guo, C., Wang, Z., Song, H., Kuang, Y., Cao, Y., & Yang, G. (2026). A narrow therapeutic window of platelet P2Y 12 reactivity in high-risk Chinese percutaneous coronary intervention patients. PeerJ. https://doi.org/10.7717/peerj.20536

Vancouver

Gong L, Liu Y, Li J, Tan S, Guo C, Wang Z, et al. A narrow therapeutic window of platelet P2Y 12 reactivity in high-risk Chinese percutaneous coronary intervention patients. PeerJ. 2026. doi:10.7717/peerj.20536

BibTeX
@article{Gong2026,
  author = {Gong, Liying and Liu, Yaxin and Li, Jingle and Tan, Shiming and Guo, Chengxian and Wang, Zhengmei and Song, Huiling and Kuang, Yun and Cao, Yu and Yang, Guoping},
  title = {A narrow therapeutic window of platelet P2Y 12 reactivity in high-risk Chinese percutaneous coronary intervention patients},
  journal = {PeerJ},
  year = {2026},
  doi = {10.7717/peerj.20536}
}
Kostenlos starten →